RxDoctor Payments Data

Stevan Milhoan, MD

Internal Medicine · Vienna, WVNPI 1780661652

Payments from drug & device makers

$2,806in general payments, 2019–2025

Across 196 payments — averaging $14.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$614
  • Novo Nordisk$269
  • Kowa Pharmaceuticals America, Inc.$242
  • Amgen$234
  • GSK$206
  • Pfizer$192
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,800100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,806 in reported general payments places this provider in the 80th percentile of 573 internal medicine providers in West Virginia.

See all internal medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$63,405
Medicare patients
194
Services billed
652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate28$33,491
OzempicSemaglutide20$32,950
EliquisApixaban37$20,950
Soliqua 100-33Insulin Glargine/Lixisenatide12$20,059
JardianceEmpagliflozin19$17,994
TrulicityDulaglutide18$16,816
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$12,533
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$11,684
PremproEstrogen,con/M-Progest Acet13$3,091
Atorvastatin Calcium292$2,240
Pantoprazole Sodium181$1,795
Dofetilide11$1,588
Famotidine112$1,561
Colestipol Hcl14$1,472
Gabapentin114$1,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$40$33,49128 claims
Novo NordiskOzempic$269$32,95020 claims
PfizerEliquis, Prempro$192$24,04150 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$88$20,05912 claims
Boehringer IngelheimJardiance$15$17,99419 claims
Lilly USA, LLCTrulicity$191$16,81618 claims
GSKTrelegy Ellipta$206$11,68419 claims
AbbVieSynthroid$92$68712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 573 internal medicine providers in West Virginia.

Other internal medicine in Vienna

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →